Sinovac Biotech (SVA) | Stock Overview & Key Data
Sinovac Biotech Ltd. | Small-cap
Sinovac Biotech Ltd. | Small-cap
Sinovac Biotech Performance Comparison
Stock Range
Today's Range
Low: $6.47
High: $6.47
on August 19, 2025
52 Week Range
Low: $6.47
High: $6.47
on August 19, 2025
on August 19, 2025
All-Time High: $12.50 on August 31, 2009
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$642.4M
EPS
-1.06
P/E Ratio (TTM)
6.66
Forward P/E
-53.92
P/B Ratio
0.05
PEG Ratio
0.02
Div. Yield
1,700.15%
ROE
-0.88%
Beta
N/A
Debt to Equity
0.02
Financial Highlights
Profitability
Gross Margin
86.71%
Operating Margin
-33.63%
Profit Margin
59.51%
Returns and Earnings
Return on Assets (TTM)
-0.78%
Return on Equity (TTM)
-0.88%
EBITDA
$72.7M
Net Income (TTM)
$-105.9M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$4.50
Quarterly Revenue Growth (YoY)
183.63%
Quarterly Earnings Growth (YoY)
303.71%
Dividend Information
Last 12-Month Dividend
$110.00
Current Dividend Yield
1,700.15%
3-Year Average Dividend Yield
850.08%
3-Year Average Annual Dividend
$36.67
3-Year Total Dividends
$110.00
Ex-Dividend Date
July 10, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Sinovac Biotech SVA | 642.44M Small-cap | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Coursera COUR | 2.00B Small-cap | -2.46% | 28.56% | 31.05% | 39.15% | 35.38% | 37.32% | -3.29% | -74.92% |
| Teradata TDC | 1.99B Small-cap | 2.42% | -1.95% | -6.80% | -13.41% | -31.12% | -24.92% | -36.73% | -14.25% |
| W.K. Kellogg KLG | 1.99B Small-cap | -0.30% | -1.46% | 28.48% | 15.73% | 28.99% | 29.50% | 120.98% | 120.98% |
| Ingevity NGVT | 2.01B Mid-cap | 2.41% | 19.45% | 30.16% | 14.30% | 39.50% | 43.50% | -23.43% | -4.88% |
| Adaptive ADPT | 1.99B Small-cap | -0.79% | 21.82% | 36.52% | 50.06% | 102.91% | 158.44% | 19.85% | -69.22% |
Sinovac Biotech Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Sinovac Biotech would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is SVA's 52-week high and low?
- In the last 52 weeks, Sinovac Biotech reached a high of $6.47 (on August 19, 2025) and a low of $6.47 (on August 19, 2025).
- What is the market cap and P/E ratio for SVA?
- Curious about Sinovac Biotech's size and valuation? Its market capitalization stands at 642.44M. When it comes to valuation, the P/E ratio (trailing twelve months) is 6.66, and the forward P/E (looking ahead) is -53.92.
- Does SVA pay dividends? If so, what's the yield?
- Yes, Sinovac Biotech is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 1,700.15%, and the company has paid an average of $36.67 per share annually over the past 3 years.
- Who are Sinovac Biotech's main competitors or similar companies to consider before investing?
When looking at Sinovac Biotech, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Coursera
COUR2.00B Consumer Defensive Education & Training Services 37.32% -3.29% Teradata
TDC1.99B Technology Software - Infrastructure -24.92% -36.73% W.K. Kellogg
KLG1.99B Consumer Defensive Packaged Foods 29.50% 120.98% Ingevity
NGVT2.01B Basic Materials Specialty Chemicals 43.50% -23.43% Adaptive
ADPT1.99B Healthcare Biotechnology 158.44% 19.85% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Sinovac Biotech Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Sinovac Biotech's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -0.88%, the Debt to Equity ratio from the most recent quarter is 0.02, and its Gross Profit Margin stands at 86.71%.
- What is the recent revenue and earnings growth for SVA?
- Looking at Sinovac Biotech's growth, its revenue over the trailing twelve months (TTM) was $448M. Compared to the same quarter last year (YoY), quarterly revenue grew by 183.63%, and quarterly earnings saw a YoY growth of 303.71%.
- How much of SVA stock is held by insiders and institutions?
- Wondering who owns Sinovac Biotech stock? Company insiders (like executives and directors) hold about N/A of the shares, while institutional investors (such as mutual funds and pension funds) own approximately N/A.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.